AbbVie faces US amended antitrust claims over Humira
MLex Summary: Employee health funds filed an amended US antitrust complaint accusing AbbVie of conspiring to block biosimilar competition to its brand name drug Humira. According to the complaint, AbbVie entered...To view the full article, register now.
Already a subscriber? Click here to view full article